| Trial ID: | L0443 |
| Source ID: | IRCT20121216011763N42
|
| Associated Drug: |
Curcumin
|
| Title: |
The effect of Curcumin-Piperine supplementation on cardiometabolic factors, hepatic steatosis and fibrosis of fibroscan results and liver function in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic fatty liver. <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
| Interventions: |
Intervention 1: Intervention group: A daily curcumin-piperine capsule(500 mg curcumin+ 5 mg piperine) will recive after meal for 12 weeks. Intervention 2: Control group: A daily placebo capsule(500 mg lactose) will recive after meal for 12 weeks.
|
| Outcome Measures: |
TG. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;TC. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;HDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;LDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.;Waist circumference. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: non-stretching tape measure.;BMI. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;ALT. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.nan
|
| Sponsor/Collaborators: |
Esfahan University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years65 years
|
| Phases: |
Not applicable
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomly, based on the permuted block randomization method, using blocks of 4 that will be blocked based on gender va
|
| Start Date: |
10/01/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
24 February 2020
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/43732
|
